ImmuSmol raises 500 000 € to advance cancer immunotherapy programme09/23/2014
ImmuSmol is pleased to announce it has raised 500 000 € to progress its monoclonal antibodies for cancer immunotherapy to in vivo proof-of-concept (POC).
Nature Article: Aryl hydrocarbon receptor control of a disease tolerance defence pathway06/15/2014
Access latest article by ImmuSmol CEO Alban Bessède
Polyclonal antibodies to Tryptophan / Kynurenine metabolites now available06/13/2014
NEW! ImmuSmol releases rabbit polyclonal antibodies against Tryptophan / Kynurenine metabolites, all validated for IHC in human samples.
Picture: L-Kynurenine detection by IHC in human colorectal cancer tissue using anti-L-Kynurenine rabbit pAb.
ImmuSmol at BioEurope Spring 201403/10/2014
ImmuSmol will be in Turin for Bioeurope Spring 2014, on March 10-12. Contact us to arrange a meeting!
Antibodies against small molecules - IHC & ELISA applications03/03/2014
A short overview of ImmuSmol's services for the development of antibodies against small molecules, and their subsequent validation for small molecule detection by ELISA or IHC.